A Study to Evaluate Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis (SERENE)

This study has been completed.
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00299130
First received: March 3, 2006
Last updated: June 10, 2014
Last verified: June 2014
  Purpose

This study evaluated the efficacy and safety of rituximab in patients with rheumatoid arthritis (RA).


Condition Intervention Phase
Rheumatoid Arthritis
Drug: Folate
Drug: Methotrexate
Drug: Methylprednisolone
Drug: Placebo
Drug: Rituximab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis

Resource links provided by NLM:


Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]

    To achieve an ACR20 required at least a 20% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 20% improvement in three of the following five additional measurements:

    • Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale [VAS]);
    • Patient's global assessment of disease activity (assessed using a 100 mm VAS);
    • Patient's assessment of pain (assessed using a 100 mm VAS);
    • Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3);
    • Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR).

    Participants who withdrew prematurely from the study prior to week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.



Secondary Outcome Measures:
  • Percentage of Participants With an ACR50 Response at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]

    To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements:

    • Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale [VAS]);
    • Patient's global assessment of disease activity (assessed using a 100 mm VAS);
    • Patient's assessment of pain (assessed using a 100 mm VAS);
    • Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3);
    • Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR).

    Participants who withdrew prematurely from the study prior to week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.


  • Percentage of Participants With an ACR70 Response at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]

    To achieve an ACR70 required at least a 70% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements:

    • Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale [VAS]);
    • Patient's global assessment of disease activity (assessed using a 100 mm VAS);
    • Patient's assessment of pain (assessed using a 100 mm VAS);
    • Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3);
    • Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR).

    Participants who withdrew prematurely from the study prior to week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.


  • Change From Baseline in Disease Activity Score (DAS28-ESR) at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]

    The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:

    • The number of swollen and tender joints assessed using the 28-joint count;
    • Erythrocyte sedimentation rate (ESR);
    • Patient's global assessment of disease activity measured on a 100 mm visual analog scale.

    The DAS28 score ranges from zero to ten. A DAS28 score above 5.1 means high disease activity whereas a DAS28 less than or equal to 3.2 indicates low disease activity. Remission is achieved by a DAS28 lower than 2.6.


  • Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity.

    A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score of less than or equal to 3.2.

    A Moderate Response is defined as either:

    • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 from Baseline and attainment of a DAS28 score of less than or equal to 5.1 or,
    • an improvement (decrease) in the DAS28 of more than 1.2 from Baseline and attainment of a DAS28 score of greater than 3.2.

    No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 of more than 5.1.


  • Percent Change From Baseline in Swollen Joint Count [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A negative percentage change from baseline score indicates an improvement.


  • Percent Change From Baseline in Tender Joint Count [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A negative percentage change from baseline score indicates an improvement.


  • Percent Change From Baseline in Patient's Global Assessment of Disease Activity [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The participant's overall assessment of their current disease activity measured on a 100 mm horizontal visual analog scale (VAS). The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A negative percentage change from baseline score indicates an improvement.


  • Percent Change From Baseline in Patient's Pain Assessment [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The participant's assessment of their current level of pain on a 100 mm horizontal visual analog scale (VAS), where the left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand extreme (100 mm) as "unbearable pain".

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A negative percentage change from baseline score indicates an improvement.


  • Percent Change From Baseline in Physician's Global Assessment of Disease Activity [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS, where the left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity".

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A negative percentage change from baseline score indicates an improvement.


  • Percent Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A negative percentage change from baseline score indicates an improvement.


  • Percent Change From Baseline in C-Reactive Protein [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    C-Reactive Protein (CRP) was measured from blood samples by a central laboratory as a marker for inflammation.

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A negative percentage change from baseline score indicates an improvement.


  • Percent Change From Baseline in Erythrocyte Sedimentation Rate [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A negative percentage change from baseline score indicates an improvement.


  • Percent Change From Baseline in Short Form 36 Health Survey (SF-36) [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions split into two major components: physical health and mental health. Under physical health are the following four domains: physical health, bodily pain, physical functioning and physical role limitations. Under the mental health domain there are four domains; mental health, vitality, social functioning, and emotional role limitation. The individual domain scores are aggregated to derive a physical-component summary score and a mental-component summary score which range from 0 to 100, with higher scores indicating a better level of functioning.

    The percentage change from baseline at each post-baseline visit was calculated as:

    [(post-baseline value minus baseline value) divided by Baseline value]*100.

    A positive percentage change from baseline score indicates an improvement.


  • Change From Baseline in Short Form 36 Health Survey (SF-36) General Health Domain Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Role Limitations Domain Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in Short Form 36 Health Survey (SF-36) Mental Health Domain Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in Short Form 36 Health Survey (SF-36) Vitality Domain Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in Short Form 36 Health Survey (SF-36) Social Functioning Domain Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in Short Form 36 Health Survey (SF-36) Emotional Role Limitations Domain Score [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.

    A positive change from baseline score indicates an improvement.


  • Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scores [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions using a value in the range of 0 (not at all) to 4 (very much). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue.

    A positive change from baseline score indicates an improvement.


  • Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

    The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:

    • The number of swollen and tender joints assessed using the 28-joint count;
    • Erythrocyte sedimentation rate (ESR);
    • Patient's global assessment of disease activity measured on a 100 mm visual analog scale.

    The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity.

    Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.


  • Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]

    The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement.

    Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22.

    An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22.

    A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.


  • Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 48 [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]

    The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement.

    Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22.

    An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22.

    A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.


  • Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 48 [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score.

    A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.

    A Moderate Response is defined as either:

    • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or,
    • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of 5.1 or higher.


  • Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 48 [ Time Frame: Week 48 ] [ Designated as safety issue: No ]

    The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:

    • The number of swollen and tender joints assessed using the 28-joint count;
    • Erythrocyte sedimentation rate (ESR);
    • Patient's global assessment of disease activity measured on a 100 mm visual analog scale.

    The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity.

    Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.


  • Percentage of Participants With an ACR50 Response at Week 48 [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]

    To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements:

    • Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale [VAS]);
    • Patient's global assessment of disease activity (assessed using a 100 mm VAS);
    • Patient's assessment of pain (assessed using a 100 mm VAS);
    • Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3);
    • Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR).

    Participants who withdrew prematurely from the study prior to week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.


  • Percentage of Participants With an ACR70 Response at Week 48 [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]

    To achieve an ACR70 required at least a 70% improvement compared with baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements:

    • Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale [VAS]);
    • Patient's global assessment of disease activity (assessed using a 100 mm VAS);
    • Patient's assessment of pain (assessed using a 100 mm VAS);
    • Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3);
    • Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR).

    Participants who withdrew prematurely from the study prior to week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.


  • Time to Repletion of Peripheral CD19+ B-cells [ Time Frame: Beginning of the first infusion (Day 1) in the last treatment cycle until repletion or the end of the study (up to 3 years, 6 months) ] [ Designated as safety issue: No ]
    Peripheral CD19+ B-cell repletion was defined as a CD19+ B-cell count that returned to the Baseline value or returned to ≥ the lower limit of normal, whichever was lower.

  • Percentage of Participants With Low Immunoglobulin Concentrations Post-rituximab Treatment [ Time Frame: Beginning of the safety follow-up period to the end of the study (up to 3 years) ] [ Designated as safety issue: No ]
    A low immunoglobulin concentration was defined as a concentration below the lower level of normal.


Enrollment: 511
Study Start Date: October 2005
Study Completion Date: July 2013
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Placebo + methotrexate

Participants received placebo intravenous infusion on Days 1 and 15. After Week 24, participants could switch to receive rituximab 500 mg (on Day 1 and Day 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate (MTX) and ≥ 5 mg/week folic acid for the duration of their participation in the study.

All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

Drug: Folate
A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
Drug: Methotrexate
A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
Drug: Methylprednisolone
Intravenous infusion
Drug: Placebo
Placebo to rituximab intravenous infusion
Drug: Rituximab
Intravenous infusion
Other Names:
  • MabThera®
  • Rituxan®
Experimental: Rituximab 500 mg + methotrexate

Participants received 500 mg rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.

All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

Drug: Folate
A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
Drug: Methotrexate
A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
Drug: Methylprednisolone
Intravenous infusion
Drug: Rituximab
Intravenous infusion
Other Names:
  • MabThera®
  • Rituxan®
Experimental: Rituximab 1000 mg + methotrexate

Participants received 1000 mg rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.

All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

Drug: Folate
A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
Drug: Methotrexate
A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
Drug: Methylprednisolone
Intravenous infusion
Drug: Rituximab
Intravenous infusion
Other Names:
  • MabThera®
  • Rituxan®

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Adult patients 18-80 years of age.
  • Rheumatoid arthritis (RA) for ≥ 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis.
  • Receiving outpatient treatment for RA.
  • Swollen joint count (SJC) ≥ 8 (66 joint count), and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline.
  • At screening, either

    • C-reactive protein (CRP) ≥ 0.6 mg/dL (6 mg/L), or
    • Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour.
  • Inadequate response to methotrexate, having received and tolerated at a dose of 10-25 mg/week it for ≥ 12 weeks.

Exclusion criteria:

  • Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA.
  • Inflammatory joint disease other than RA, or other systemic autoimmune disorder.
  • Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16.
  • Surgery within 12 weeks of study or planned within 24 weeks of randomization.
  • Previous treatment with any approved or investigational biological agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00299130

Sponsors and Collaborators
Genentech, Inc.
Roche Pharma AG
Investigators
Study Director: Anshu Vashishtha, M.D. PhD Genentech, Inc.
  More Information

No publications provided by Genentech, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00299130     History of Changes
Other Study ID Numbers: U2973g, WA17045
Study First Received: March 3, 2006
Results First Received: February 21, 2013
Last Updated: June 10, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Genentech, Inc.:
RA
Rituxan
SERENE

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Methotrexate
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Rituximab
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Anti-Inflammatory Agents
Antiemetics
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Autonomic Agents
Central Nervous System Agents
Dermatologic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on October 23, 2014